Esperion Therapeutics Inc (NASDAQ:ESPR) price on current trading day, fall -0.94% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.05.
A look at the stock’s price movement, the close in the last trading session was $1.06, moving within a range at $0.9701 and $1.11. The beta value (5-Year monthly) was 0.861. Turning to its 52-week performance, $3.94 and $1.04 were the 52-week high and 52-week low respectively. Overall, ESPR moved -32.26% over the past month.
Esperion Therapeutics Inc’s market cap currently stands at around $207.74 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-03.
Analysts have a consensus estimate of 54.97M for the company’s revenue for the quarter, with a low and high estimate of 44.4M and 63.8M respectively. The average forecast suggests down to a -60.09% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 348.5M, representing a 4.87% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ESPR is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 6 recommend ESPR as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ESPR’s current price about -28.40% and -36.21% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 21.57, while 7-day volatility ratio is 11.81% and 7.52% in the 30-day chart. Further, Esperion Therapeutics Inc (ESPR) has a beta value of 0.84, and an average true range (ATR) of 0.11. Analysts have given the company’s stock an average 52-week price target of $8, forecast between a low of $8 and high of $8. Looking at the price targets, the low is -661.9% off current price level while to achieve the yearly target high, price needs to move -661.9%. Nonetheless, investors will most likely welcome a -661.9% jump to $8 which is the analysts’ median price.
If we refocus on Esperion Therapeutics Inc (NASDAQ:ESPR), historical trading data shows that trading volumes averaged 5.24 over the past 10 days and 4.32 million over the past 3 months. The company’s latest data on shares outstanding shows there are 195.85 million shares.
The 1.76% of Esperion Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 58.83% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 28.9 million on 2025-03-14, giving us a short ratio of 7.27. The data shows that as of 2025-03-14 short interest in Esperion Therapeutics Inc (ESPR) stood at 1464.9999 of shares outstanding, with shares short rising to 28.1 million registered in 2025-02-14. Current price change has pushed the stock -52.27% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ESPR stock continues to rise going into the next quarter.
